Güven Naile Merve, Karaömerlioğlu İrem, Arıoğlu İnan Ebru, Can Eke Benay
Ankara University, Faculty of Pharmacy, Department of Pharmaceutical Toxicology, Ankara, Türkiye.
Ankara University, Graduate School of Health Sciences, Ankara, Türkiye.
Turk J Pharm Sci. 2024 Mar 25;21(1):81-86. doi: 10.4274/tjps.galenos.2023.87450.
This study investigated the impact of a high-fat diet streptozotocin (STZ)-induced diabetes and dapagliflozin treatment on hepatic protein expression of CYP3A4.
In our study, 34 male Sprague-Dawley rats were randomly divided into four groups: Control, high-fat diet and STZ-induced diabetes, dapagliflozin-treated control, and dapagliflozin-treated diabetes. In the microsomes obtained from the livers of these rats, the protein expression levels of CYP3A4 were determined by Western blotting.
Hepatic CYP3A4 protein expression levels in the control group treated with dapagliflozin were significantly decreased compared with those in the control group. In addition, hepatic CYP3A4 protein expression levels were decreased in dapagliflozin-treated diabetic Sprague-Dawley rats compared with those in both control and diabetic group rats, but the difference between the groups was not statistically significant.
According to these two results, the use of dapagliflozin inhibited hepatic CYP3A4 protein expression.
本研究调查了高脂饮食联合链脲佐菌素（STZ）诱导的糖尿病以及达格列净治疗对细胞色素P450 3A4（CYP3A4）肝脏蛋白表达的影响。
在我们的研究中，34只雄性Sprague-Dawley大鼠被随机分为四组：对照组、高脂饮食联合STZ诱导糖尿病组、达格列净治疗对照组以及达格列净治疗糖尿病组。在从这些大鼠肝脏获取的微粒体中，通过蛋白质免疫印迹法测定CYP3A4的蛋白表达水平。
与对照组相比，接受达格列净治疗的对照组大鼠肝脏中CYP3A4蛋白表达水平显著降低。此外，与对照组和糖尿病组大鼠相比，接受达格列净治疗的糖尿病Sprague-Dawley大鼠肝脏中CYP3A4蛋白表达水平降低，但组间差异无统计学意义。
根据这两个结果，使用达格列净可抑制肝脏CYP3A4蛋白表达。
